Literature DB >> 14742258

A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.

Dominik N Muller1, Juergen Theuer, Erdenechimeg Shagdarsuren, Eva Kaergel, Horst Honeck, Joon-Keun Park, Marija Markovic, Eduardo Barbosa-Sicard, Ralf Dechend, Maren Wellner, Torsten Kirsch, Anette Fiebeler, Michael Rothe, Hermann Haller, Friedrich C Luft, Wolf-Hagen Schunck.   

Abstract

Cytochrome P450 (CYP)-dependent arachidonic acid (AA) metabolites are involved in the regulation of renal vascular tone and salt excretion. The epoxygenation product 11,12-epoxyeicosatrienoic acid (EET) is anti-inflammatory and inhibits nuclear factor-kappa B activation. We tested the hypothesis that the peroxisome proliferator-activated receptor-alpha-activator fenofibrate (Feno) induces CYP isoforms, AA hydroxylation, and epoxygenation activity, and protects against inflammatory organ damage. Double-transgenic rats (dTGRs) overexpressing human renin and angiotensinogen genes were treated with Feno. Feno normalized blood pressure, albuminuria, reduced nuclear factor-kappa B activity, and renal leukocyte infiltration. Renal epoxygenase activity was lower in dTGRs compared to nontransgenic rats. Feno strongly induced renal CYP2C23 protein and AA-epoxygenase activity under pathological and nonpathological conditions. In both cases, CYP2C23 was the major isoform responsible for 11,12-EET formation. Moreover, we describe a novel CYP2C23-dependent pathway leading to hydroxy-EETs (HEETs), which may serve as endogenous peroxisome proliferator-activated receptor-alpha activators. The capacity to produce HEETs via CYP2C23-dependent epoxygenation of 20-HETE and CYP4A-dependent hydroxylation of EETs was reduced in dTGR kidneys and induced by Feno. These results demonstrate that Feno protects against angiotensin II-induced renal damage and acts as inducer of CYP2C23-mediated epoxygenase activities. We propose that CYP-dependent EET/HEET production may serve as an anti-inflammatory control mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742258      PMCID: PMC1602252          DOI: 10.1016/s0002-9440(10)63142-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage.

Authors:  D N Muller; V Heissmeyer; R Dechend; F Hampich; J K Park; A Fiebeler; E Shagdarsuren; J Theuer; M Elger; B Pilz; V Breu; K Schroer; D Ganten; R Dietz; H Haller; C Scheidereit; F C Luft
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

Review 2.  Eicosanoid regulation of the renal vasculature.

Authors:  J D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2000-12

3.  Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

Authors:  H Bloomfield Rubins; J Davenport; V Babikian; L M Brass; D Collins; L Wexler; S Wagner; V Papademetriou; G Rutan; S J Robins
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

Review 4.  Peroxisome proliferator-activated receptors in inflammation control.

Authors:  P Delerive; J C Fruchart; B Staels
Journal:  J Endocrinol       Date:  2001-06       Impact factor: 4.286

5.  Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators.

Authors:  P Delerive; P Gervois; J C Fruchart; B Staels
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

6.  Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice.

Authors:  H Honeck; V Gross; B Erdmann; E Kärgel; R Neunaber; A F Milia; W Schneider; F C Luft; W H Schunck
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

7.  Fenofibrate lowers blood pressure in two genetic models of hypertension.

Authors:  R K Shatara; D W Quest; T W Wilson
Journal:  Can J Physiol Pharmacol       Date:  2000-05       Impact factor: 2.273

8.  Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.

Authors:  D N Müller; E M Mervaala; R Dechend; A Fiebeler; J K Park; F Schmidt; J Theuer; V Breu; N Mackman; T Luther; W Schneider; D Gulba; D Ganten; H Haller; F C Luft
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

9.  CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR.

Authors:  M H Wang; F Zhang; J Marji; B A Zand; A Nasjletti; M Laniado-Schwartzman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-01       Impact factor: 3.619

10.  Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia.

Authors:  I J Jonkers; F H de Man; A van der Laarse; M Frölich; J A Gevers Leuven; A M Kamper; G J Blauw; A H Smelt
Journal:  J Hypertens       Date:  2001-04       Impact factor: 4.844

View more
  28 in total

1.  Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Mohammed Al-Shabrawey; Mong-Heng Wang; Krishna Rao Maddipati; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

2.  Lipoprotein lipase and heart size.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2006-01-17       Impact factor: 4.599

3.  High potassium intake enhances the inhibitory effect of 11,12-EET on ENaC.

Authors:  Peng Sun; Dao-Hong Lin; Peng Yue; Houli Jiang; Katherine H Gotlinger; Michal L Schwartzman; John R Falck; Mohan Goli; Wen-Hui Wang
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

4.  Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension.

Authors:  Kimberly Gilbert; Hui Nian; Chang Yu; James M Luther; Nancy J Brown
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

Review 5.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

6.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

7.  Association of a CYP4A11 variant and blood pressure in black men.

Authors:  James V Gainer; Michael S Lipkowitz; Chang Yu; Michael R Waterman; Elliott P Dawson; Jorge H Capdevila; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

8.  Cyp2c44 epoxygenase in the collecting duct is essential for the high K+ intake-induced antihypertensive effect.

Authors:  Wen-Hui Wang; Chengbiao Zhang; Dao-Hong Lin; Lijun Wang; Joan P Graves; Darryl C Zeldin; Jorge H Capdevila
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-25

9.  Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice.

Authors:  Komal Sodhi; Kazuyoshi Inoue; Katherine H Gotlinger; Martina Canestraro; Luca Vanella; Dong Hyun Kim; Vijay L Manthati; Sreenivasulu Reddy Koduru; John R Falck; Michal L Schwartzman; Nader G Abraham
Journal:  J Pharmacol Exp Ther       Date:  2009-08-28       Impact factor: 4.030

10.  Effect of fish oil on monoepoxides derived from fatty acids during cardiac surgery.

Authors:  Emmanuel Akintoye; Jason H Y Wu; Tao Hou; Xiaoling Song; Jun Yang; Bruce Hammock; Dariush Mozaffarian
Journal:  J Lipid Res       Date:  2016-01-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.